These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29478699)

  • 1. α-Synuclein Oligomers Induce a Unique Toxic Tau Strain.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Gerson JE; Kayed R
    Biol Psychiatry; 2018 Oct; 84(7):499-508. PubMed ID: 29478699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.
    Gerson JE; Farmer KM; Henson N; Castillo-Carranza DL; Carretero Murillo M; Sengupta U; Barrett A; Kayed R
    Mol Neurodegener; 2018 Mar; 13(1):13. PubMed ID: 29544548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein.
    Sengupta U; Puangmalai N; Bhatt N; Garcia S; Zhao Y; Kayed R
    Mol Neurobiol; 2020 Jun; 57(6):2741-2765. PubMed ID: 32350746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo.
    Fagerqvist T; Näsström T; Ihse E; Lindström V; Sahlin C; Tucker SM; Kasaryan A; Karlsson M; Nikolajeff F; Schell H; Outeiro TF; Kahle PJ; Lannfelt L; Ingelsson M; Bergström J
    Amyloid; 2013 Dec; 20(4):233-44. PubMed ID: 24053224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein modulates tau spreading in mouse brains.
    Bassil F; Meymand ES; Brown HJ; Xu H; Cox TO; Pattabhiraman S; Maghames CM; Wu Q; Zhang B; Trojanowski JQ; Lee VM
    J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33091110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered α-Synuclein and Tau.
    Bhasne K; Sebastian S; Jain N; Mukhopadhyay S
    J Mol Biol; 2018 Aug; 430(16):2508-2520. PubMed ID: 29704492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct α-synuclein strains differentially promote tau inclusions in neurons.
    Guo JL; Covell DJ; Daniels JP; Iba M; Stieber A; Zhang B; Riddle DM; Kwong LK; Xu Y; Trojanowski JQ; Lee VM
    Cell; 2013 Jul; 154(1):103-17. PubMed ID: 23827677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Tau and α-Synuclein Pathology in the Visual System.
    Rahimi J; Milenkovic I; Kovacs GG
    J Parkinsons Dis; 2015; 5(2):333-40. PubMed ID: 25737267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated accumulation of retinal α-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease.
    Mammadova N; Summers CM; Kokemuller RD; He Q; Ding S; Baron T; Yu C; Valentine RJ; Sakaguchi DS; Kanthasamy AG; Greenlee JJ; Heather West Greenlee M
    Neurobiol Dis; 2019 Jan; 121():1-16. PubMed ID: 30218757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
    Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
    Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.
    Rey NL; George S; Steiner JA; Madaj Z; Luk KC; Trojanowski JQ; Lee VM; Brundin P
    Acta Neuropathol; 2018 Jan; 135(1):65-83. PubMed ID: 29209768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.
    Choi ML; Gandhi S
    FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
    Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
    J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and α-synuclein fibrils.
    Elbatrawy AA; Ademoye TA; Alnakhala H; Tripathi A; Zami A; Ostafe R; Dettmer U; Fortin JS
    Bioorg Med Chem; 2024 Feb; 100():117613. PubMed ID: 38330847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
    Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
    ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
    Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.
    Li X; James S; Lei P
    J Mol Neurosci; 2016 Nov; 60(3):298-304. PubMed ID: 27629562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.